Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.” ...

She joined Amgen’s Epidemiology department in 2004, driving its growth from a small group of eight employees into Amgen’s ...

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...

Amgen discovers, develops ... may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving ...

“Amgen Inc. (NASDAQ:AMGN) is a large-cap global biotech company with a diverse portfolio of marketed and pipeline products. Amgen’s discovery pipeline has led the company to broaden its focus ...